September 30, 2024

Unlocking the future of antibody-drug conjugates

Labcorp bioanalytical services has supported nearly half of the approved antibody - drug conjugates (ADCs) on market today. Access the on-demand session as we discuss LBA and LC-MS insights gleaned from our deep bioanalytical experience with ADCs, bioanalytical opportunities and challenges we have encountered, how innovative strategies can overcome key issues, and a forward-looking perspective on ADC bioanalytical strategies for this rapidly evolving market.
October 24, 2024

Labcorp Announces 2024 Third Quarter Results

Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance:
October 23, 2024

Impact of implant location on in vivo therapeutic response and immune modulation in the MC38-luc mouse colon carcinoma model

EORTC-NCI-AACR (ENA) Symposium 2024 -- Mouse tumor models play an essential role in investigating tumor biology, evaluating therapeutic response and predicting clinical outcomes. The location of the tumor, whether implanted subcutaneously or orthotopically, can significantly impact its growth, spread and response to treatment. The MC38-luc mouse colon carcinoma model is widely used in preclinical cancer research for studying tumor biology and immunotherapy responses. The aim of this study was to evaluate the antitumor efficacy and immunomodulatory effects of immune checkpoint inhibitors (ICIs) in subcutaneous (SC) and orthotopic (OT) MC38-luc mouse models.
October 22, 2024

Comparison of manual vs. automated extraction techniques for RCL clinical monitoring

ESGCT 2024 -- Transduced cell therapies, e.g., CAR-T cells, offer a powerful therapeutic strategy for treatment of various cancers and auto-immune diseases. CAR-T and analogous therapies are often transduced using lentiviral vectors to integrate the chimeric antigen receptor (CAR) construct into the cell line. The use of lentiviral vectors introduces the risk of patient exposure, with a particular concern regarding replication competent lentivirus (RCL). In addition to RCL testing during cell product release, there is a necessity to establish the absence of RCL over the course of clinical studies assessing lentiviral-transduced cell therapy products. The current FDA recommendation for clinical monitoring is for testing of blood/PBMCs for the absence of RCL before dosing and, periodically over the course of at least the first year following dosing. In addition to target-specific transduced cell therapy vector copy number (VCN) method development and validation, Labcorp supports RCL testing for clinical samples with a validated VSV-G envelope protein targeting qPCR method. Recent further validation work has refined the previously manual whole blood extraction method to an automated process using half the sample input and aligning with extractions supporting VCN analyses.
October 20, 2024

Receptor occupancy assay development challenges for rare targets of bispecific drugs

AAPS PharmSci360 2024 -- Receptor occupancy (RO) assays allow for the quantification of binding of therapeutics to their intended targets on the surface of different cell subsets. Flow cytometry-based RO assays are a strong tool for preclinical and clinical development, providing rapid, high-throughput and quantitative measure for PK/PD modelling. Research challenges remain however when RO assays are developed and validated for rare low expressing targets. Herein we present an example of such an assay, its challenges, and the steps taken to resolve performance issues with impact on data and RO calculations.
October 20, 2024

Validation of a quantitative PCR (qPCR) assay for the detection and quantification of replication competent lentivirus for patient monitoring in lentiviral vector-based cell therapy studies

AAPS PharmSci360 2024 -- Lentiviral vectors are a common delivery system for various cell therapies, such as CAR/TCR-T cell therapies. There is a potential risk for replication competent lentivirus (RCL) in patients receiving lentiviral vector-based cell therapies. There is a critical need for regular RCL monitoring in patients. PCR-based assays for RCL detection are recommended by the FDA. Our objective was to validate a qPCR assay based on quantification of vesicular stomatitis virus glycoprotein (VSV-G) envelope protein gene sequence for RCL.